Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the brain and spinal cord. Characterized by loss of upper and lower motor neurons (UMNs/LMNs), its progression is relentless and is currently incurable.
- Average survival ranges from 2 to 5 years from the time of diagnosis.
- >50% live >3 years, 25% live >5 years, 10% live >10 years, 5% live up to 20 years
- Sporadic ALS form is 90–95% of all cases. It includes a number of overlapping syndromes, such as pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy, and primary lateral sclerosis.
- Familial ALS (FALS) is most commonly inherited as an autosomal dominant condition and less so as an autosomal recessive disease. This is clinically similar to sporadic ALS but probably represents a distinct entity pathologically and biochemically.
- Guam ALS and Parkinson-dementia complex are ALS-like syndromes often, but not always, associated with Parkinson syndrome and dementia. Guam ALS is prevalent among the Chamorro Indians of Guam and rare in the United States.
- System(s) affected: nervous
- Synonym(s): motor neuron disease (MND); Lou Gehrig disease; Charcot disease; ALS
- Infantile and juvenile spinal muscular atrophies are conditions distinct from ALS, both clinically and pathologically.
- Symptoms of ALS may inappropriately be attributed to age.
- Uncommon among affected individuals
- If pregnancy did occur, the only foreseeable difficulties would be related to weakness.
- In United States, 5,000 newly diagnosed per year
- Rate = 2 to 5/100,000 per year
- Estimated 20,000 Americans may have the disease at any given time without socioeconomic boundaries.
- ALS is more common among white males, non-Hispanics, and persons aged 60 to 69 years (1).
- Peak age onset of 58 to 63 years old for sporadic
- Peak age onset 47 to 52 years old for familial
- Predominant age: 40 to 70 years, average age 55 years old
- Predominant sex: male > female in sporadic ALS:
- After 70 years and in FALS: male = female
Etiology and Pathophysiology
- Sporadic ALS: unknown cause, but elevated levels of glutamate have been found in serum and CSF
- FALS: neurodegenerative disease passed on directly or indirectly by skipping generation (2)
- Guam ALS and Parkinson-dementia complex: caused by eating bats that feed on cycad seeds (high concentration of neurotoxic amino acid)
- Degeneration of the UMNs/LMNs with gliosis replacing lost neurons; leads to spinal cord atrophy, thin ventral roots, and loss of large myelinated fibers in motor nerves
- Progressive weakness of both skeletal and smooth muscles that leads to progressive loss of function related to movement, speech, swallowing, and breathing
- FALS, most common (5–10% of cases); can be autosomal dominant or autosomal recessive; X-linked dominant cases have been reported. 50–60% of FALS will have a detectable known genetic mutation.
- C9orf72 repeat expansions found in 2011 in 30–40% of FALS
- Gene locus has been localized to the long arm of chromosome 21 at position 22.11 and encodes the superoxide dismutase (SOD1) enzyme. This accounts for 15–20% of FALS cases and 5% of sporadic cases.
- FIG4 gene accounts for 3% of FALS.
- Mutations in several genes, including fused in sarcoma (FUS), angiogenin gene (ANG, encodes for angiogenin and ribonuclease), TAR DNA-binding protein (TARDBP), and TDP-43 (helps regulate transcription and alternative splicing), have been discovered to be associated with familial and sporadic ALS.
- Overall, 22 mutations have been reported with current research continuing to discover new genes associated with ALS.
- Family history
- Age >40 years and <70 years
- Maternal age and increased number of younger siblings each may be associated with risk for ALS.
- Formaldehyde exposure (but not pesticide/herbicide exposure)
- Military personnel, due to environmental exposures
Genetic counseling is advised if there is a family history of ALS; however, sporadic ALS is not associated with genetic transmission.
There's more to see -- the rest of this topic is available only to subscribers.
Domino, Frank J., et al., editors. "Amyotrophic Lateral Sclerosis." 5-Minute Clinical Consult, 27th ed., Wolters Kluwer, 2020. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688447/all/Amyotrophic_Lateral_Sclerosis.
Amyotrophic Lateral Sclerosis. In: Domino FJF, Baldor RAR, Golding JJ, et al, eds. 5-Minute Clinical Consult. Wolters Kluwer; 2020. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688447/all/Amyotrophic_Lateral_Sclerosis. Accessed May 29, 2023.
Amyotrophic Lateral Sclerosis. (2020). In Domino, F. J., Baldor, R. A., Golding, J., & Stephens, M. B. (Eds.), 5-Minute Clinical Consult (27th ed.). Wolters Kluwer. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688447/all/Amyotrophic_Lateral_Sclerosis
Amyotrophic Lateral Sclerosis [Internet]. In: Domino FJF, Baldor RAR, Golding JJ, Stephens MBM, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2020. [cited 2023 May 29]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688447/all/Amyotrophic_Lateral_Sclerosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Amyotrophic Lateral Sclerosis ID - 1688447 ED - Domino,Frank J, ED - Baldor,Robert A, ED - Golding,Jeremy, ED - Stephens,Mark B, BT - 5-Minute Clinical Consult, Updating UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688447/all/Amyotrophic_Lateral_Sclerosis PB - Wolters Kluwer ET - 27 DB - Medicine Central DP - Unbound Medicine ER -